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The industry landscape is evolving rapidly and requires new and innovative approaches for more rapidly
addressing the growing global demand for drug products as well as the challenges of unpredictability and
inflexibility that have historically burdened the industry. Over the past two years, the industry’s herculean response
to the COVID-19 pandemic has proven that with the proper focus, investment, science, and manufacturing
technologies, these historic challenges can be overcome as well as establishing new benchmarks for how the
industry can perform in the future to ensure availability of drug products and therapies to the global patient base
Prefabricated modular construction of cleanrooms, utilities, and facility structures, is an innovative approach to
building new manufacturing facilities that the industry has benefited from and is currently being utilised in critical
COVID related projects. Prefabricated and modular facilities have been utilized in many industries such as food,
chemical, and consumer products in the past, and have started to see significant adoption within the pharma and
biopharma industries over the past ten years. This has largely been driven by the need to reduce project timelines,
improve capability and flexibility, and minimize the risks associated with traditional construction for manufacturing
facilities. It has helped as well to make Biopharma manufacturing more accessible to emerging regions, where in
the past biomanufacturing was too complex to establish.
For a drug manufacturer to shift its strategy for designing and building its new manufacturing facilities using a
prefabricated approach, it typically must perform its own comparative assessment of prefabricated modular
construction to traditional construction which will include critical factors such as capital investment, speed to
market, schedule, return on investment, flexibility for new products and network capacity, cost of ownership
through facility lifecycle, etc. Multiple stakeholders including but not limited to the C-Suite executives, engineering,
operations, quality, regulatory, and EHS should all have their input considered as part of the evaluation.
The presentation will include a summary of the typical performance requirements for cleanrooms and an overview
of the different types for cleanroom construction. We will then evaluate the impact of using prefabricated
cleanroom construction. The project drivers and influences which will help determine the best construction
approach to meet the overall project goals and achieve the manufacturing objectives will be discussed. A short
introduction to G-CON and its modular POD cleanroom technology will also be provided as well as the benefits of
implementing the prefabricated approach for cleanroom construction.
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